Compare MNSB & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MNSB | MDXH |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | Belgium |
| Employees | 171 | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.3M | 149.0M |
| IPO Year | N/A | 2021 |
| Metric | MNSB | MDXH |
|---|---|---|
| Price | $24.81 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 54.8K | ★ 186.7K |
| Earning Date | 04-20-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.50 | $30.78 |
| Revenue Next Year | $3.77 | $18.31 |
| P/E Ratio | $12.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.86 | $1.67 |
| 52 Week High | $25.17 | $5.33 |
| Indicator | MNSB | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 65.79 | 30.28 |
| Support Level | $20.84 | $1.96 |
| Resistance Level | $25.14 | $2.37 |
| Average True Range (ATR) | 0.71 | 0.14 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 66.67 | 0.00 |
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.